37873875|t|Unveiling the Molecular Footprint: Proteome-Based Biomarkers for Alzheimer's Disease.
37873875|a|Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Early and accurate diagnosis of AD is crucial for implementing timely interventions and developing effective therapeutic strategies. Proteome-based biomarkers have emerged as promising tools for AD diagnosis and prognosis due to their ability to reflect disease-specific molecular alterations. There is of great significance for biomarkers in AD diagnosis and management. It emphasizes the limitations of existing diagnostic approaches and the need for reliable and accessible biomarkers. Proteomics, a field that comprehensively analyzes the entire protein complement of cells, tissues, or bio fluids, is presented as a powerful tool for identifying AD biomarkers. There is a diverse range of proteomic approaches employed in AD research, including mass spectrometry, two-dimensional gel electrophoresis, and protein microarrays. The challenges associated with identifying reliable biomarkers, such as sample heterogeneity and the dynamic nature of the disease. There are well-known proteins implicated in AD pathogenesis, such as amyloid-beta peptides, tau protein, Apo lipoprotein E, and clusterin, as well as inflammatory markers and complement proteins. Validation and clinical utility of proteome-based biomarkers are addressing the challenges involved in validation studies and the diagnostic accuracy of these biomarkers. There is great potential in monitoring disease progression and response to treatment, thereby aiding in personalized medicine approaches for AD patients. There is a great role for bioinformatics and data analysis in proteomics for AD biomarker research and the importance of data preprocessing, statistical analysis, pathway analysis, and integration of multi-omics data for a comprehensive understanding of AD pathophysiology. In conclusion, proteome-based biomarkers hold great promise in the field of AD research. They provide valuable insights into disease mechanisms, aid in early diagnosis, and facilitate personalized treatment strategies. However, further research and validation studies are necessary to harness the full potential of proteome-based biomarkers in clinical practice.
37873875	65	84	Alzheimer's Disease	Disease	MESH:D000544
37873875	86	105	Alzheimer's disease	Disease	MESH:D000544
37873875	107	109	AD	Disease	MESH:D000544
37873875	128	154	neurodegenerative disorder	Disease	MESH:D019636
37873875	184	201	cognitive decline	Disease	MESH:D003072
37873875	206	217	memory loss	Disease	MESH:D008569
37873875	251	253	AD	Disease	MESH:D000544
37873875	414	416	AD	Disease	MESH:D000544
37873875	562	564	AD	Disease	MESH:D000544
37873875	870	872	AD	Disease	MESH:D000544
37873875	946	948	AD	Disease	MESH:D000544
37873875	1226	1228	AD	Disease	MESH:D000544
37873875	1287	1304	Apo lipoprotein E	Gene	348
37873875	1310	1319	clusterin	Gene	1191
37873875	1332	1344	inflammatory	Disease	MESH:D007249
37873875	1690	1692	AD	Disease	MESH:D000544
37873875	1780	1782	AD	Disease	MESH:D000544
37873875	1957	1959	AD	Disease	MESH:D000544
37873875	2053	2055	AD	Disease	MESH:D000544
37873875	Association	MESH:D000544	348
37873875	Association	MESH:D000544	1191

